TRODELVY is indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
ADDITIONAL INFORMATION FOR READERS PROVIDED BY IMMUNOMEDICS, INC.
This independent, peer-reviewed article may contain data, conclusions, and recommendations that do not conform to the FDA-approved labeling for the product discussed herein. TRODELVY should be used only as specified in the Prescribing Information. Please see full Prescribing Information for TRODELVY. This article is being disseminated at the expense of Immunomedics, Inc. The opinions expressed in this article do not necessarily reflect those of Immunomedics, Inc.
The following authors of the publication have received research funding from Immunomedics, Inc.: A. Bardia, I.A. Mayer, L.T. Vahdat, S.M. Tolaney, S.J. Isakoff, J.R. Diamond, J. O’Shaughnessy, R.L. Moroose, A.D. Santin, V.G. Abramson, N.C. Shah, H.S. Rugo, and K. Kalinsky. The following author of the publication has acted as paid consultant or advisor for Immunomedics, Inc.: A.M. Sweidan. The following authors are or have been employed by Immunomedics, Inc.: D.M. Goldenberg, R. Iannone, S. Washkowitz, R.M. Sharkey, and W.A. Wegener.
Please be advised that the value of this reprint will be tracked and may be publicly disclosed per the responsibilities of Immunomedics, Inc., under federal and state laws.
By clicking the “OK” button below, I acknowledge that I’ve read and agree to the above information.